Ultragenyx Pharm Stock Price, News & Analysis

Ultragenyx Pharmaceutical (NASDAQ: RARE) has announced the grant of stock options and restricted stock units to 11 newly hired non-executive officers. The grant includes 11,035 stock options and 17,710 restricted stock units, approved by the compensation committee and awarded under the Ultragenyx Employment Inducement Plan.

The stock options have a ten-year term with an exercise price of $38.20 per share, reflecting the closing price on April 14, 2023. The restricted stock units vest over four years, while the stock options vest at the first anniversary and continue monthly thereafter, contingent on continuous employment.

Ultragenyx focuses on developing novel therapies for rare diseases, aiming to address high unmet medical needs.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at Guggenheim’s Genomic Medicines and Rare Disease Days on April 3, 2023, at 10:45 a.m. ET. The event will be accessible via a live and archived webcast on the company’s website. Ultragenyx focuses on developing therapies for serious rare and ultrarare genetic diseases, boasting a diverse portfolio of approved therapies. The company aims to provide safe, effective treatments efficiently, addressing high unmet medical needs in the rare disease sector. The webcast replay will be available for one year following the event.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced the grant of stock options and restricted stock units to ten newly hired non-executive officers. A total of 7,130 stock options and 5,885 restricted stock units were awarded under the Ultragenyx Employment Inducement Plan, approved by the compensation committee of the board of directors. The stock options have a ten-year term with an exercise price of $40.22, corresponding to the closing stock price on the grant date of March 16, 2023. Both stock options and restricted units will vest over four years, promoting retention among new employees dedicated to addressing rare diseases.

Ultragenyx Pharmaceutical has announced the promotion of Dr. Eric Crombez to chief medical officer and executive vice president, effective May 1, 2023. He succeeds Dr. Camille Bedrosian, who will transition to a strategic advisory role. Dr. Crombez, who has been pivotal in developing clinical programs for rare genetic disorders, previously served as CMO for gene therapy and inborn errors of metabolism. Under his leadership, the company aims to enhance its pipeline focused on treatments for rare diseases. Ultragenyx is committed to delivering therapies with high unmet needs efficiently and effectively.

Ultragenyx Pharmaceutical (NASDAQ: RARE) announced that CEO Emil D. Kakkis will speak at the Orphan Neuro Panel during Cowen's 43rd Annual Health Care Conference on March 7, 2023, at 10:30 a.m. ET. This event highlights the company's commitment to developing therapies for rare genetic diseases. The live and archived webcast will be available on the company's website for 30 days following the event. Ultragenyx focuses on creating innovative products to meet urgent medical needs with no existing treatments available, led by a team skilled in rare disease therapeutics.

Ultragenyx Pharmaceutical reported a total revenue of $363.3 million for 2022, marking a growth from $351.4 million in 2021. Key drivers included Crysvita, contributing $279.4 million, and Dojolvi with $55.6 million. For 2023, the company projects total revenue between $425 million and $450 million, with Crysvita revenue expected to reach $325 million to $340 million. Despite strong revenue growth, Ultragenyx reported a net loss of $707.4 million for 2022, an increase from $454 million in 2021. The company also holds a healthy cash balance of $896.7 million as of December 31, 2022.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced a conference call on February 16, 2023, at 5:00 p.m. ET, to discuss its financial results for Q4 and the full year ending December 31, 2022. This call will provide insights into the company's performance in developing therapies for rare genetic diseases. Interested participants can access the live call via the company's website, and a replay will be available for one year. Ultragenyx focuses on novel therapies to meet the high unmet medical needs of patients with rare diseases.

Ultragenyx Pharmaceutical reported preliminary total product revenue for 2022 between $352 million to $356 million, with Crysvita revenue estimated at $257 million to $258 million and Dojolvi revenue at $55 million to $56 million. For 2023, the company guides total revenue of $425 million to $450 million, driven by Crysvita and Dojolvi. The cash balance at year-end 2022 was approximately $900 million. Expectations for net cash used in operations in 2023 are under $400 million. The company emphasizes advancements in its pipeline and a focus on reducing cash spending.